GILEAD SCIENCES, INC. (GILD) vs JOHNSON & JOHNSON (JNJ)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | GILD | JNJ |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $29.44B | $94.19B |
| Revenue growth (YoY) | ▲ 2.4% | ▲ 6.0% |
| Net income | $8.51B | $26.8B |
| Gross margin | 78.8% | 67.9% |
| Diluted EPS | $6.78 | $11.03 |
| Insider net (6 mo) | +385.1K sh • 18 sells • 0 buys | −40.8K sh • 7 sells • 0 buys |
| Institutional owners | 46 | 47 |
| Institutional value held | $98.74B | $294.77B |
| Next earnings (est.) | Around Oct 29, 2026 | Around Jan 20, 2027 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About GILEAD SCIENCES, INC. (GILD)
Gilead Sciences, Inc. is a biopharmaceutical company headquartered in Foster City, California, operating in more than 35 countries, dedicated to discovering, developing and delivering innovative medicines addressing unmet medical needs in virology, oncology… Read more →
About JOHNSON & JOHNSON (JNJ)
Johnson & Johnson, incorporated in New Jersey in 1887, is a global healthcare holding company with approximately 138,200 full-time-equivalent employees engaged in the research, development, manufacture, and sale of a broad range of healthcare products. Read more →
Source: SEC EDGAR.